What's Going On With Neurological Disease Focused Trevena On Thursday?
What's Going On With Neurological Disease Focused Trevena On Thursday?
Shares of Trevena Inc (NASDAQ:TRVN) are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro.
據Benzinga Pro的數據，Trevena Inc.（納斯達克：TRVN）的股票在週四交易時出現下跌，成交量爲2365萬股。
The company released preclinical data from two separate research collaborations.
該公司發佈了兩個不同研究合作的臨床前數據。
The first studies examined the cellular mechanism of analgesic effects of TRV045, a novel S1P1 receptor modulator, in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN).
第一項研究檢查了TRV045的鎮痛作用機制，TRV045是一種新型S1P1受體調節劑，檢測採用化療引起的外周神經病變（CIPN）小鼠模型。
The second set of studies was from a separate, ongoing collaboration with the NIH-supported Epilepsy Therapy Screening Program (ETSP), which studied the use of TRV045 in three different preclinical models, examining its potential effects on acute seizure protection and its potential ability to modify seizure development, or epileptogenesis.
第二組研究來自與美國國立衛生研究院支持的癲癇療法篩選計劃（ETSP）的另一個正在進行的合作項目，研究了TRV045在三種不同的臨床前模型中的應用，研究其可能對急性癲癇發作的保護效應，並研究其可能修改發作和癲癇發展。
In this study, TRV045 did not cause S1P1R functional desensitization or S1PR1 protein reduction despite repeated dosing over 14 days.
在這項研究中，在14天的重複給藥過程中，TRV045並沒有引起S1P1R功能性失效或S1PR1蛋白降低。
In contrast, Novartis AG's (NYSE:NVS) Gilenya (fingolimod), an approved S1PR modulator, demonstrated significant S1P1R functional desensitization and protein reduction in this model.
相反，諾華製藥（紐交所：NVS）的Gilenya（指甲酸酯），一種S1PR調節劑，證實該模型中的S1P1R功能性失效和蛋白降低顯著。
Repeated fingolimod (1 mg/kg, once a day for 14 days) dosing decreased such 35SGTPgS binding by approximately 70% compared with vehicle, while repeated TRV045 oral dosing (10 mg/kg, once a day for 14 days) had no effect.
在這種模型中，重複的Gilenya（1mg/kg，每天一次，持續14天）給藥導致約70%的35SGTPgS結合相比於用車劑時下降。而重複的TRV045口服給藥（每天10mg/kg，持續14天）沒有任何影響。
S1PR1 protein expression indicated that repeated fingolimod treatment caused an approximately 30% reduction in S1P1R protein in the spinal cord, while repeated TRV045 treatment had no effect.
S1PR1蛋白表達表明，重複的Gilenya治療導致脊髓S1P1R蛋白降低約30%，而重複的TRV045治療沒有任何影響。
Similar effects were seen in the region of the periaqueductal gray; both regions play important roles in pain transmission.
類似的效果也在中腦導水管周圍灰質區域中看到；這兩個區域在疼痛傳導中起着重要作用。
A validated model of seizure induction in mice was used in a preclinical study.
小鼠誘發癲癇研究採用了一個經過驗證的模型。
At the 30mg/kg dose, TRV045 demonstrated a statistically significant increase in time to the first myoclonic (whole-body) twitch (31.6 seconds TRV045 vs 26.0 seconds vehicle, p=0.02).
在30mg/kg的劑量下，TRV045表現出統計學顯著延遲首個肌陣攣（全身）抽搐的時間（31.6秒TRV045對比26.0秒車劑，P=0.02）。
This dose of TRV045 also demonstrated an increase in the time to generalized clonus (33.9 seconds TRV045 vs. 28.7 seconds vehicle, p=0.056).
這個劑量的TRV045也展現出了延遲全身陣攣發生的時間（33.9秒TRV045對比28.7秒車劑，P=0.056）。
A separate study used a validated model of acute anti-seizure effect in rats. A dose-dependent protection was observed across the dose range, reaching 7 of 8 rats protected at the 30 mg/kg dose level and an estimated effective dose for 50% of the population (ED50) of 18 mg/kg.
另一項研究採用了大鼠急性抗癲癇效應的經過驗證的模型。在劑量範圍內觀察到了劑量依賴性的保護效果，在30mg/kg劑量中可保護8只大鼠中的7只，50%人群的有效劑量估計值（ED50）爲18mg/kg。
The NIH-supported Epilepsy Therapy Screening Program plans to initiate additional studies of the anti-seizure potential of TRV045.
美國國立衛生研究院支持的癲癇療法篩選計劃計劃啓動TRV045的抗癲癇潛力的其他研究。
Although the initial assessment of the potential anti-epileptogenic effect of TRV045 did not demonstrate a statistically significant difference on the outcomes studied here, these results will assist in subsequent considerations of other dose and treatment duration in future seizure prevention studies.
儘管TRV045的潛在抗癲癇效應的最初評估在此處研究的結果上沒有表現出顯著差異，但這些結果將有助於今後考慮其他劑量和治療持續時間以進行癲癇預防研究。
Price Action: TRVN shares are down 33.7% at $0.2349 at last check Thursday.
截至週四最新數據，TRVN股票下跌33.7%，爲0.2349美元。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。